Lack of data leads to double NICE no for Novartis's Glivec
This article was originally published in Scrip
NICE, the National Institute for health and Clinical Excellence in the UK, is set to decline NHS funding for high doses of Novartis's Glivec (imatinib) for treating unresectable and or metastatic gastrointestinal stromal tumors (GIST), it says in preliminary draft guidance published today. It based the decision on a lack of "good quality clinical and cost-effectiveness data".
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.